quinoxalines has been researched along with mitoxantrone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dorr, RT; Landowski, TH; Pourpak, A | 1 |
| Bastos, ML; Carvalho, F; Carvalho, RA; Costa, VM; Gomes, AS; Pinto, M; Reis-Mendes, A; Remião, F; Sousa, E | 1 |
2 other study(ies) available for quinoxalines and mitoxantrone
| Article | Year |
|---|---|
Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Catenated; DNA, Kinetoplast; Docetaxel; Humans; Isoquinolines; Male; Melphalan; Mice; Mice, SCID; Mitoxantrone; Naphthalimides; Prostatic Neoplasms; Protein Binding; Quinoxalines; RNA Interference; Taxoids; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays | 2007 |
Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy.
Topics: Adenine; Adenosine Triphosphate; Animals; Antineoplastic Agents; Autophagy; Cardiotoxicity; Cell Line; Dose-Response Relationship, Drug; Lactic Acid; Membrane Potential, Mitochondrial; Mitoxantrone; Myocytes, Cardiac; Quinoxalines; Rats; Time Factors | 2017 |